SkinCure Oncology

SkinCure Oncology, founded in 2016 in the United States, has garnered attention as a pioneer in the healthcare industry with its innovative approach to skin cancer treatment. The company's slogan, "SkinCure Oncology offers GentleCure™, the most comprehensive approach to nonsurgical treatment for common skin cancer," succinctly encapsulates its mission. SkinCure Oncology distinguishes itself as the sole provider of GentleCure™, an advanced nonsurgical treatment for basal cell carcinoma, squamous cell carcinoma, and other skin cancers through Image-Guided SRT. The company's strategic partnerships with quality-focused dermatologists and Mohs surgeons have enabled it to introduce cancer center-level radiation therapy to physician offices. SkinCure Oncology empowers practices with the necessary clinical, administrative, and operational support, ensuring they are fully equipped to deliver Image-Guided SRT treatment. The proprietary Sensus SRT-100 Vision™ platform, featuring high-frequency ultrasound imaging, stands as a testament to their commitment to advanced technology. This platform facilitates the delivery of calibrated doses of X-ray energy, employing adaptive radiotherapy protocols to eradicate malignant cancer cells while preserving the surrounding healthy tissue, thus optimizing both clinical and cosmetic outcomes for patients. The most recent milestone for SkinCure Oncology came on 24th September 2019 with a significant $30.00M Private Equity Round investment secured from Seacoast Capital Partners, underscoring the confidence investors have in the company's groundbreaking approach. As a trailblazer in the healthcare and health and wellness industries, SkinCure Oncology's innovative solutions and strategic alliances position it as a potential game-changer in the field of skin cancer treatment.